MIAMI--(BUSINESS WIRE)--Diverse Biotech has been granted USPTO patent approval of its novel CUSP synthesis platform creating an entirely new class of drugs that are part-antibody and part-cannabinoid in one new molecule. Starting with DBT-50201, its novel PEMBROLIZUMAB compound, Diverse expects to develop multiple treatments for many diseases with highly unmet needs. According to John Patrick, M.D., Executive Vice President and Chief Medical Officer for Diverse Biotech, “We are very excited about being granted our first patent for our monoclonal antibody class of drugs with our flagship drug DBT-50201 which represents a significant advancement for PEMBROLIZUMAB. We expect that our monoclonal drug DBT-50201 will mirror the results we have seen thus far in trials with our Temozolomide drug used to treat Glioblastomas (brain cancer), DBT-30180. We have observed significant increases in potency and efficacy with our CUSP technology averaging about 2,000% when compared to standard chemotherapy alone. Coupled with other potential decreases in toxicity, these results represent a major step forward in the treatment and cure of multiple cancers.”
About Diverse Biotech: Diverse Biotech Inc. is a privately held drug discovery and development company, that licenses out hit-to-lead (early stage novel molecules) and advanced (late-stage, de-risked) therapeutic molecules, that are pre-positioned for the clinical trial process with the FDA. Diverse is very excited about its CUSP technology platform because it currently represents over 73,000 different license opportunities in many different drug classes including, but not limited to, cancer therapeutics, cardiovascular drugs, anti-hypertensives, anti-viral, antibiotics, diabetes drugs, neuroleptics, and even basic drugs such as non-steroidal anti-inflammatories. The significance of Diverse Biotech’s CUSP technology is the cooperation of two or more drugs or other agents to produce a combined effect greater than the sum of their separate effects. CUSP also creates a better delivery system which gives drugs a much greater potency and efficacy while significantly reducing toxicities and morbidities typically seen with certain drugs. Diverse Biotech licenses out its technology to bring a wide variety of new drugs to market, changing the standard of care in medicine.
